一种用于角膜内皮修复的药用组合物
By using a conjugate of fibroblast growth factor and laminin, the repair of corneal endothelial cells is promoted, solving the treatment problem of corneal endothelial dysfunction and restoring corneal transparency and cell density. This also treats symptoms such as pain and blurred vision caused by corneal endothelial dysfunction.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- EYE INST OF SHANDONG FIRST MEDICAL UNIV
- Filing Date
- 2023-05-17
- Publication Date
- 2026-07-17
AI Technical Summary
There is a lack of effective, low-invasive treatments for corneal endothelial cell damage, especially since corneal endothelial dysfunction due to low proliferative capacity is difficult to repair, and donor corneal transplant resources are limited.
A conjugate of fibroblast growth factor and laminin is used to prepare a pharmaceutical composition that promotes the growth, migration, adhesion, proliferation and differentiation of corneal endothelial cells, constructs endothelial cells to repair the basement membrane, and is used in combination with drugs or medical devices to treat corneal endothelial damage.
It effectively promotes the repair of corneal endothelial cells, restores corneal transparency and thickness, inhibits scar hyperplasia, improves cell density and morphology, and treats symptoms such as pain and blurred vision caused by corneal endothelial dysfunction.
Smart Images
Figure CN116603054B_ABST